Replagal Enzyme Replacement Therapy for Children With Fabry Disease



Status:Archived
Conditions:Hematology, Metabolic
Therapuetic Areas:Hematology, Pharmacology / Toxicology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

An Open Label Clinical Trial of Replagal Enzyme Replacement Therapy In Children With Fabry Disease Who Have Completed Study TKT023 or Who Are Naive to Enzyme Replacement Therapy


The objectives of this clinical trial are to evaluate: 1) the safety of multiple biweekly
(ie, every other week) intravenous (IV) doses of agalsidase alfa over an extended period of
time, for patients who have completed 6 months of agalsidase alfa therapy in TKT023 in the
US and Canada (Cohort 1), and for patients treatment-naïve for enzyme replacement therapy
(Cohort 2); 2) the pharmacokinetics of agalsidase alfa in the pediatric population, and 3)
the exploration of efficacy of Replagal in terms of proteinuria, heart rate variability,
clinical outcomes, and renal function (Cohorts 1 and 2); sweating and left ventricular (LV)
mass (Cohort 1 only). Safety will be determined for both cohorts by standard clinical and
laboratory measurements.


TKT029 is an open label multi-center study to assess the safety of enzyme replacement
therapy with agalsidase alfa in children with Fabry disease, who have completed 6 months of
agalsidase alfa therapy in study TKT023 (Cohort 1) or are treatment-naïve (Cohort 2) and
meet all inclusion/exclusion criteria of this study. The study will consist of treatment
with agalsidase alfa for 52 weeks, with periodic reassessments by Shire HGT for continuation
beyond the 52 weeks. A decision on the part of the study sponsor to terminate the study may
be made at any time.

Study tests performed during the Baseline visit in TKT023 will serve as the baseline
evaluation for the TKT029 study for patients in Cohort 1 and at Week -1 for patients in
Cohort 2. The subjects will receive 0.2 mg/kg IV agalsidase alfa every other week. A
number of safety assessments will be performed at Week 13, Week 25, and thereafter, every 26
weeks.

The final study visit will follow 30 days after the last study drug infusion for patients
who withdraw early from the study, at which time a final safety evaluation will be
performed. Patients who complete the study will be telephone interviewed 30 days after
their last study infusion for resolution of any outstanding AEs or concomitant medication
changes.


We found this trial at
10
sites
St. Louis, Missouri 63110
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
Allentown, Pennsylvania 18102
?
mi
from
Allentown, PA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
2018 W Clinch Ave
Knoxville, Tennessee 37916
(865) 541-8000
East Tennessee Children's Hospital East Tennessee Children's Hospital is a not-for-profit, private, independent pediatric medical...
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Lake Charles, Louisiana 70601
?
mi
from
Lake Charles, LA
Click here to add this to my saved trials
550 1st Ave
New York, New York 10016
(212) 263-7300
New York University Langone Medical Center NYU NYU Langone Medical Center, a world-class, patient-centered, integrated,...
?
mi
from
New York, NY
Click here to add this to my saved trials
Stafford, Virginia 22556
?
mi
from
Stafford, VA
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials